Biogen Inc. expects its GAAP and non-GAAP results for the second quarter of 2026 to include acquired in-process research and development, upfront and milestone expenses of approximately $164 million on a pre-tax basis. This charge is projected to reduce GAAP and non-GAAP net income per diluted share by approximately $0.95 for the quarter.

Q3 2026 Outlook

For the third quarter of 2026, Biogen anticipates similar expenses ranging from approximately $290 million to $320 million. These charges relate to potential milestones and transactions that have not yet closed. The company estimates this will impact GAAP and non-GAAP net income per diluted share by between $1.75 and $1.95.

Financial Impact Summary

The following table outlines the expected charges and their impact on earnings per share for the specified periods.

Needham analyst Ami Fadia has maintained a Buy rating on Biogen (NASDAQ: BIIB) while raising the stock's price target to $256 from $255 following a meeting with company management. The adjustment reflects continued confidence in the company's performance, driven by positive uptake in its key products and strategic acquisitions. The revised target represents a $1 increase from the prior valuation ceiling.

Product Performance and Strategy

Fadia noted that Spinraza HD uptake has been "quite positive," with demand matching Spinraza’s launch levels. This growth is driven by both new and returning patients. The analyst also highlighted Biogen's progress across in-market products, late-stage assets, and business development, including the recent RayThera acquisition.

Regarding the Alzheimer’s drug Leqembi, Fadia pointed out that predicting the impact of the new under-the-skin (SC) injection on patient numbers is difficult due to frequent switching between injections and IV drips. Many patients prefer clinic-based IV treatments due to a lack of caregivers at home. While more doctors are utilizing blood tests for diagnosis, traditional PET brain scans remain prevalent. The use of blood tests is expected to accelerate patient enrollment in the AHEAD 3-45 clinical study.

Strategic Collaborations and Pipeline

On the Apellis front, management identified a potential collaboration opportunity with Syfovre to expand commercial capabilities for both companies. However, Biogen remains in a learning phase with Empaveli due to limited nephrology experience. Fadia also mentioned that full data for Phase 2 CELIA, expected at the AAIC, should clarify the rationale for advancing diranersen to the registrational stage.

Analyst Metrics

The table below summarizes the updated analyst metrics for Biogen.

Shares of Biogen had risen by 1.05% to $218.29 at the time of publication on Monday.